CN105021828B - By detecting that three phase colorectal carcinoma patients serums predict tumor patient prognosis - Google Patents
By detecting that three phase colorectal carcinoma patients serums predict tumor patient prognosis Download PDFInfo
- Publication number
- CN105021828B CN105021828B CN201510427069.7A CN201510427069A CN105021828B CN 105021828 B CN105021828 B CN 105021828B CN 201510427069 A CN201510427069 A CN 201510427069A CN 105021828 B CN105021828 B CN 105021828B
- Authority
- CN
- China
- Prior art keywords
- patients
- mip
- prognosis
- rnates
- ifn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 33
- 238000004393 prognosis Methods 0.000 title claims abstract description 22
- 210000002966 serum Anatomy 0.000 title claims abstract description 20
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 11
- 201000010989 colorectal carcinoma Diseases 0.000 title claims 3
- 206010028980 Neoplasm Diseases 0.000 title abstract description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 description 14
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 108010012236 Chemokines Proteins 0.000 description 6
- 102000019034 Chemokines Human genes 0.000 description 6
- 238000000611 regression analysis Methods 0.000 description 5
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 201000002313 intestinal cancer Diseases 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 102100023688 Eotaxin Human genes 0.000 description 2
- 101710139422 Eotaxin Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
- 101000742599 Homo sapiens Vascular endothelial growth factor D Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 108700012920 TNF Proteins 0.000 description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000016583 Anus disease Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 101710091439 Major capsid protein 1 Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 108010082093 Placenta Growth Factor Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 238000011353 adjuvant radiotherapy Methods 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
- G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明涉及RNATES、MIP‑1b、IFN‑g的新用途，可通过检测三期结直肠肿瘤患者血清中RNATES、MIP‑1b、IFN‑g水平预测肿瘤患者预后。其优点表现在：本发明第一次证明通过检测患者血清中RNATES、MIP‑1b、IFN‑g的水平可以预测三期结直肠癌患者的预后状态。
The present invention relates to a new application of RNATES, MIP-1b, and IFN-g, which can predict the prognosis of tumor patients by detecting the levels of RNATES, MIP-1b, and IFN-g in serum of patients with colorectal tumors of three stages. Its advantages are as follows: the present invention proves for the first time that the prognosis status of stage III colorectal cancer patients can be predicted by detecting the levels of RNATES, MIP‑1b and IFN‑g in the patient's serum.
Description
技术领域technical field
本发明涉及结直肠癌技术领域，具体地说，是通过检测三期结直肠肿瘤患者血清中RNATES、MIP-1b、IFN-g水平预测肿瘤患者预后。The invention relates to the technical field of colorectal cancer, specifically, predicting the prognosis of tumor patients by detecting the levels of RNATES, MIP-1b and IFN-g in the serum of patients with three-stage colorectal tumors.
背景技术Background technique
结直肠肿瘤是常见的恶性肿瘤之一，发病率在男女中都很高，在全球肿瘤死亡病例中位居第四位。目前，三期肠癌患者是指初次诊断时患者即有淋巴结的转移，对于三期肠癌病人，手术切除和辅助放化疗是标准的治疗方案，然而仍然有四分之一的三期肠癌患者接受了标准的治疗之后，仍然出现了复发和远处转移的情况。Colorectal tumor is one of the common malignant tumors, with a high incidence rate in both men and women, and it ranks fourth in the global cancer death cases. At present, patients with stage III bowel cancer refer to patients with lymph node metastasis when they are first diagnosed. For patients with stage III bowel cancer, surgical resection and adjuvant radiotherapy and chemotherapy are the standard treatment options. However, there are still a quarter of patients with stage III bowel cancer After the patient received standard treatment, recurrence and distant metastasis still occurred.
影响肠癌患者预后的因素有很多，很多研究表明免疫系统失衡可以影响患者的预后。最近，很多研究表明，免疫因子在调节肿瘤患者的化疗敏感性上起到了重要作用。趋化因子是一类小分子多肽，肿瘤微环境中的趋化因子一般是肿瘤细胞自身分泌的或者是被招募而来，越来越多的证据表明，肿瘤微环境中趋化因子的聚集跟抗肿瘤的免疫反应相关。肿瘤细胞的增值、侵袭和转移都受到趋化因子的调节。趋化因子可以在患者的外周血中检测到，因此，检测患者外周血中趋化因子的浓度是潜在预测肿瘤患者预后的手段。There are many factors that affect the prognosis of bowel cancer patients, and many studies have shown that immune system imbalance can affect the prognosis of patients. Recently, many studies have shown that immune factors play an important role in regulating the chemosensitivity of tumor patients. Chemokines are a class of small molecular polypeptides. Chemokines in the tumor microenvironment are generally secreted or recruited by tumor cells. More and more evidence shows that the accumulation of chemokines in the tumor microenvironment is closely related to Anti-tumor immune response. The proliferation, invasion and metastasis of tumor cells are regulated by chemokines. Chemokines can be detected in the peripheral blood of patients. Therefore, detecting the concentration of chemokines in peripheral blood of patients is a potential means of predicting the prognosis of cancer patients.
目前，已经有研究表明IL-6(白细胞趋化因子6)、IL-10和VEGF(血管生长因子)的血清水平是反应结直肠肿瘤患者预后的一个重要指标，我们团队前期的工作也发现IL-22的在患者血清和肿瘤组织中的水平都与结直肠肿瘤患者的化疗抵抗以及总体生存率相关。At present, studies have shown that the serum levels of IL-6 (leukocyte chemoattractant 6), IL-10 and VEGF (vascular growth factor) are an important indicator of the prognosis of patients with colorectal tumors. Our team's previous work also found that IL-10 The levels of -22 in patient serum and tumor tissue are correlated with chemotherapy resistance and overall survival in patients with colorectal tumors.
然而，以前的研究都是基于一个或者很少几个因子的检测，本次试验运用更加先进的高通量Luminex200技术，这个技术一次试验可以同时检测40多个细胞因子的表达水平，与传统的酶联免疫吸附试验(ELISA)相比，这种技术需要的临床样本更少，结果更加精确可信。虽然，已经有人用这个方法在病人血清中进行过试验，也得出一些跟预后相关的细胞因子，但是，专门针对三期结直肠癌病人的试验，目前没有人进行研究，我们是第一家。However, the previous studies were all based on the detection of one or a few factors. This test uses the more advanced high-throughput Luminex200 technology. This technology can detect the expression levels of more than 40 cytokines at the same time in one test, which is different from the traditional one. Compared with enzyme-linked immunosorbent assay (ELISA), this technique requires fewer clinical samples, and the results are more accurate and reliable. Although some people have used this method to test in patient serum, and some cytokines related to prognosis have been obtained, but no one has conducted research on patients with stage III colorectal cancer. We are the first .
发明内容Contents of the invention
本发明的目的是针对现有技术中的不足，提供RNATES、MIP-1b、IFN-g的新用途。The purpose of the present invention is to provide new uses of RNATES, MIP-1b and IFN-g aiming at the deficiencies in the prior art.
本发明的再一的目的是，提供一种筛选预测三期结直肠肿瘤患者预后的细胞因子的方法。Another object of the present invention is to provide a method for screening cytokines that predict the prognosis of patients with stage III colorectal tumors.
本发明的另一的目的是，提供一种治疗三期结直肠肿瘤的药物。Another object of the present invention is to provide a drug for treating three-stage colorectal tumors.
为实现上述目的，本发明采取的技术方案是：RNATES、MIP-1b、IFN-g在制备预测三期结直肠肿瘤患者预后的试剂中的应用。In order to achieve the above object, the technical scheme adopted by the present invention is: the application of RNATES, MIP-1b, and IFN-g in the preparation of reagents for predicting the prognosis of patients with colorectal tumors in the third stage.
所述的试剂检测三期结直肠肿瘤患者血清中RNATES、MIP-1b或IFN-g的水平。The reagent detects the levels of RNATES, MIP-1b or IFN-g in serum of patients with three-stage colorectal tumors.
一种预测三期结直肠肿瘤患者预后的试剂盒，所述的试剂盒检测三期结直肠肿瘤患者血清中RNATES、MIP-1b或IFN-g的水平。A kit for predicting the prognosis of patients with stage III colorectal tumors. The kit detects the levels of RNATES, MIP-1b or IFN-g in serum of patients with stage III colorectal tumors.
一种检测方法，所述的方法检测三期结直肠肿瘤患者血清中RNATES、MIP-1b或IFN-g的水平。A detection method, the method detects the levels of RNATES, MIP-1b or IFN-g in the serum of patients with stage III colorectal tumors.
一种预测三期结直肠肿瘤患者预后评分的方法，所述的方法检测三期结直肠肿瘤患者血清中RNATES、MIP-1b或IFN-g的水平，并根据RNATES、MIP-1b或IFN-g的水平进行评分。A method for predicting the prognosis score of patients with three-stage colorectal tumors, the method detects the levels of RNATES, MIP-1b or IFN-g in serum of patients with three-stage colorectal tumors, and according to RNATES, MIP-1b or IFN-g level is scored.
为实现上述第二个目的，本发明采取的技术方案是：一种筛选预测三期结直肠肿瘤患者预后的细胞因子的方法，所述的方法检测病人血液中细胞因子的浓度情况，根据最小P值法确定每个细胞因子的cutoff值，然后根据cutoff值将病人分为高表达组和低表达组，接着运用Graphpad作图软件分析两组之间的生存差异，从而判断不同细胞因子对患者预后的影响。In order to achieve the above-mentioned second purpose, the technical solution adopted by the present invention is: a method for screening cytokines for predicting the prognosis of patients with stage III colorectal tumors, the method detects the concentration of cytokines in the patient's blood, and according to the minimum P The cutoff value of each cytokine was determined by the cutoff value method, and then the patients were divided into high expression group and low expression group according to the cutoff value, and then the survival difference between the two groups was analyzed by using Graphpad mapping software, so as to judge the effect of different cytokines on the prognosis of patients Impact.
所述的方法使用45因子Luminex200试剂盒检测病人血液中45个细胞因子的浓度情况。Said method uses 45 factors Luminex200 kit to detect the concentration of 45 cytokines in the patient's blood.
为实现上述第三个目的，本发明采取的技术方案是：治疗结直肠肿瘤的药物，所述的药物能够提高结直肠肿瘤患者血清中RNATES、MIP-1b水平或降低结直肠肿瘤患者血清中IFN-g水平。In order to achieve the above-mentioned third purpose, the technical solution adopted by the present invention is: a drug for treating colorectal tumors, which can increase the levels of RNATES and MIP-1b in the serum of patients with colorectal tumors or reduce the level of IFN in the serum of patients with colorectal tumors -g levels.
本发明优点在于：The present invention has the advantage that:
本发明第一次证明通过检测患者血清中RNATES、MIP-1b、IFN-g的水平可以预测三期结直肠癌患者的预后状态。The present invention proves for the first time that the prognosis status of stage III colorectal cancer patients can be predicted by detecting the levels of RNATES, MIP-1b and IFN-g in the patient's serum.
附图说明Description of drawings
附图1是MIP-1b多因素cox回归分析的结果。Accompanying drawing 1 is the result of the multivariate cox regression analysis of MIP-1b.
附图2是IFN-g多因素cox回归分析的结果。Accompanying drawing 2 is the result of IFN-g multivariate cox regression analysis.
附图3是RNATES多因素cox回归分析的结果。Figure 3 is the result of RNATES multivariate cox regression analysis.
具体实施方式detailed description
下面结合附图对本发明提供的具体实施方式作详细说明。The specific embodiments provided by the present invention will be described in detail below in conjunction with the accompanying drawings.
实施例1Example 1
试验方法experiment method
病人：patient:
连续收集了从2010年到2012年间在新华医院结直肠肛门疾病外科进行手术治疗的357例三期肠癌病人的血清，在这357例病人中其中323例病人有完整的2年DFS随访资料。From 2010 to 2012, the serum of 357 patients with stage III colorectal cancer undergoing surgical treatment in the Department of Colorectal and Anal Diseases Surgery of Xinhua Hospital was continuously collected. Among these 357 patients, 323 patients had complete 2-year DFS follow-up data.
方法method
应用Ebioscience公司的45因子Luminex200试剂盒，检测病人血液中45个细胞因子的浓度情况，根据ROC曲线确定每个细胞因子的cutoff值，然后根据cutoff值将病人分为高表达组和低表达组，接着运用graphpad作图软件分析两组之间的生存差异，从而判断不同细胞因子对患者预后的影响。The 45-factor Luminex200 kit from Ebioscience was used to detect the concentration of 45 cytokines in the patient's blood, and the cutoff value of each cytokine was determined according to the ROC curve, and then the patients were divided into high-expression group and low-expression group according to the cutoff value. Then, the graphpad software was used to analyze the survival difference between the two groups, so as to judge the influence of different cytokines on the prognosis of patients.
结果：result:
运用单因素cox回归分析发现IFN-r、IL-8、IL-10、VEGFA、MIP-1a、MIP-1b、RNATES、LIF、EOTAXIN、IP10、PIGF、NGF、HGF、VEGFD、CA199、TNFa、GMCSF 17个细胞因子是影响结直肠癌患者预后的独立危险因素(表1)，然后运用多因素cox回归分析发现RNATES、MIP-1b、IFN-g仍然是影响患者预后的因素，与患者的DFS密切相关(图1，2，3)。Using single factor cox regression analysis, it was found that IFN-r, IL-8, IL-10, VEGFA, MIP-1a, MIP-1b, RNATES, LIF, EOTAXIN, IP10, PIGF, NGF, HGF, VEGFD, CA199, TNFa, GMCSF Seventeen cytokines are independent risk factors affecting the prognosis of patients with colorectal cancer (Table 1), and then using multivariate cox regression analysis, it is found that RNATES, MIP-1b, and IFN-g are still factors affecting the prognosis of patients, which are closely related to the DFS of patients. Correlation (Figures 1, 2, 3).
结论：in conclusion:
本项发明第一次证明通过检测患者血清中RNATES、MIP-1b、IFN-g的水平可以预测三期结直肠癌患者的预后状态。This invention proves for the first time that the prognosis status of stage III colorectal cancer patients can be predicted by detecting the levels of RNATES, MIP-1b and IFN-g in the patient's serum.
表1Table 1
实施例2Example 2
检测患者血清中RNATES、MIP-1b或IFN-g的水平预测三期结直肠癌患者的预后状态的试剂、试剂盒或检测方法等。A reagent, kit or detection method, etc. for detecting the levels of RNATES, MIP-1b or IFN-g in the patient's serum to predict the prognosis of patients with stage III colorectal cancer.
特别地，所述的试剂、试剂盒或检测方法同时检测RNATES、MIP-1b和IFN-g的水平。In particular, the reagent, kit or detection method simultaneously detects the levels of RNATES, MIP-1b and IFN-g.
实施例3Example 3
能够提高结直肠肿瘤患者血清中RNATES、MIP-1b水平或降低结直肠肿瘤患者血清中IFN-g水平的药物或许能够提高三期结直肠肿瘤患者的生存率，甚至治疗结直肠肿瘤。Drugs that can increase the serum levels of RNATES and MIP-1b in patients with colorectal tumors or reduce the levels of IFN-g in the serum of patients with colorectal tumors may be able to improve the survival rate of patients with stage III colorectal tumors, and even treat colorectal tumors.
以上所述仅是本发明的优选实施方式，应当指出，对于本技术领域的普通技术人员，在不脱离本发明方法的前提下，还可以做出若干改进和补充，这些改进和补充也应视为本发明的保护范围。The above is only a preferred embodiment of the present invention, it should be pointed out that for those of ordinary skill in the art, without departing from the method of the present invention, some improvements and supplements can also be made, and these improvements and supplements should also be considered Be the protection scope of the present invention.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510427069.7A CN105021828B (en) | 2015-07-20 | 2015-07-20 | By detecting that three phase colorectal carcinoma patients serums predict tumor patient prognosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510427069.7A CN105021828B (en) | 2015-07-20 | 2015-07-20 | By detecting that three phase colorectal carcinoma patients serums predict tumor patient prognosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105021828A CN105021828A (en) | 2015-11-04 |
| CN105021828B true CN105021828B (en) | 2017-07-28 |
Family
ID=54411945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510427069.7A Active CN105021828B (en) | 2015-07-20 | 2015-07-20 | By detecting that three phase colorectal carcinoma patients serums predict tumor patient prognosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105021828B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109975547A (en) * | 2018-02-28 | 2019-07-05 | 中山大学 | Application of the RANTES detection reagent in terms of preparing diagnosis of colorectal carcinoma agent |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ544432A (en) * | 2005-12-23 | 2009-07-31 | Pacific Edge Biotechnology Ltd | Prognosis prediction for colorectal cancer using a prognositc signature comprising markers ME2 and FAS |
| CN105755112B (en) * | 2010-07-14 | 2019-06-07 | 视觉科技生物私人有限公司 | The diagnosis of colorectal cancer |
| WO2013079309A1 (en) * | 2011-11-28 | 2013-06-06 | Fundació Privada Institució Catalana De Recerca I Estudis Avançats | Methods and kits for the prognosis of colorectal cancer |
-
2015
- 2015-07-20 CN CN201510427069.7A patent/CN105021828B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| A prognostic classifier consisting of 17 circulating cytokines is a novel predictor of overall survival for metastatic colorectal cancer patients;Zhi-Yuan Chen,et al.;《International Journal of Cancer》;20140611;第136卷(第3期);第584-592页，具体参见摘要和585页材料与方法 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105021828A (en) | 2015-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Auezova et al. | Association of preoperative levels of selected blood inflammatory markers with prognosis in gliomas | |
| Sreekanthreddy et al. | Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis | |
| Popescu et al. | Potential serum biomarkers for glioblastoma diagnostic assessed by proteomic approaches | |
| Kwon et al. | Neutrophil and lymphocyte counts as clinical markers for stratifying low-risk prostate cancer | |
| Argiris et al. | Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer | |
| Labidi-Galy et al. | Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors | |
| Zhang et al. | Evaluation of preoperative hematologic markers as prognostic factors and establishment of novel risk stratification in resected pN0 non-small-cell lung cancer | |
| Reitter et al. | Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients | |
| CN103733065A (en) | Molecular diagnostic test for cancer | |
| Lee et al. | A novel detection method of non–small cell lung cancer using multiplexed bead-based serum biomarker profiling | |
| Ferrin et al. | Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV‐infected cirrhotic patients by 2‐D DIGE | |
| Sukowati et al. | Serum stem cell growth factor beta for the prediction of therapy response in hepatocellular carcinoma | |
| Chang et al. | Prognostic cytokine markers in peripheral blood for oral cavity squamous cell carcinoma identified by multiplexed immunobead-based profiling | |
| Wang et al. | Correlation between ovarian neoplasm and serum levels of osteopontin: a meta-analysis | |
| JP2016521141A5 (en) | ||
| Jin et al. | The prognostic value of neutrophil–lymphocyte ratio is superior to derived neutrophil–lymphocyte ratio in advanced gastric cancer treated with preoperative chemotherapy and sequential r0 resection: a 5-year follow-up | |
| Wang et al. | Serum cytokine profiles of melanoma patients and their association with tumor progression and metastasis | |
| Mapalagamage et al. | High levels of serum angiopoietin 2 and angiopoietin 2/1 ratio at the critical stage of dengue hemorrhagic fever in patients and association with clinical and biochemical parameters | |
| Giannakakis et al. | Overexpression of SMARCE1 is associated with CD8+ T-cell infiltration in early stage ovarian cancer | |
| Kim et al. | Prognostic impact of pretreatment albumin to globulin ratio in patients with diffuse large B-cell lymphoma treated with R-CHOP | |
| Jin et al. | Bioinformatics analysis of potential therapeutic targets and prognostic biomarkers amid CXC chemokines in ovarian carcinoma microenvironment | |
| US20190376969A1 (en) | Nasopharyngeal protein biomarkers of acute respiratory virus infection and methods of using same | |
| Zhang et al. | Expression of growth‑regulated oncogene‑1, hepatocyte growth factor, platelet‑derived growth factor‑AA and soluble E‑selectin and their association with high‑risk human papillomavirus infection in squamous cell carcinoma of the uterine cervix | |
| Spaks et al. | Diagnostic value of circulating CXC chemokines in non-small cell lung cancer | |
| Wang et al. | Irradiation-induced dynamic changes of gene signatures reveal gain of metastatic ability in nasopharyngeal carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |